Clinical, laboratory, and chest CT features of severe versus non-severe pediatric patients with COVID-19 infection among different age groups

Hoseinyazdi, Meisam; Esmaeilian, Saeid; Jahankhah, Reza; Teimouri, Arash; Sherbaf, Farzaneh Ghazi; Rafiee, Faranak; Jalli, Reza; Hooshmandi, Sedighe

doi:10.1186/s12879-021-06283-5

Table 1 Comparison of clinical and laboratory features between severe and non-severe pediatric patients with COVID-19

From: Clinical, laboratory, and chest CT features of severe versus non-severe pediatric patients with COVID-19 infection among different age groups

	Total		Severe		Non severe		P- value
	N	Mean (SD)/percentage	N	Mean (SD)/percentage	N	Mean (SD)/percentage	P- value
Age, year	53	9.58 (5.35)	25	8.33 (5.51)	28	10.69 (5.05)	0.12
Sex
Male	22	41.5%	9	36.0%	13	46.4%	0.44
Female	31	58.5%	16	64.0%	15	53.6%	0.44
Disease onset to hospital admission duration	53	3.0 (2.0–6.25)	25	4.0 (2.0–7.5)	28	3.0 (1.25–7.0)	0.38
Hospital duration	53	5.37 (4.22)	25	7.16 (5.09)	28	3.78 (2.39)	0.01
ICU duration	53	0.69 (2.46)	25	1.48 (3.45)	28	0.00 (0.00)	0.01
ICU admission
Yes	6	11.3%	6	24.0%	0	0.0%	0.01
No	47	88.7%	19	76.0%	28	100.0%	0.01
Fever
Yes	42	79.2%	19	76.0%	23	82.1%	0.58
No	11	20.8%	6	24.0%	5	17.9%	0.58
Dry cough
Yes	40	75.5%	21	84.0%	19	67.9%	0.17
No	13	24.5%	4	16.0%	9	32.1%	0.17
Nasal congestion
Yes	5	9.4%	3	8.0%	2	10.7%	0.74
No	48	90.6%	23	92.0%	25	89.3%	0.74
Poor feeding
Yes	2	28.6%	1	20.0%	1	50.0%	0.43
No	5	71.4%	4	80.0%	1	50.0%	0.43
Body pain
Yes	14	30.4%	4	20.0%	10	38.5%	0.18
No	32	69.6%	16	80.0%	16	61.6%	0.18
Nausea
Yes	12	26.1%	6	30.0%	6	23.1%	0.60
No	34	73.9%	14	70.0%	20	76.9%	0.60
Diarrhea
Yes	5	9.4%	4	16.0%	1	3.6%	0.12
No	48	90.6%	21	84.0%	27	96.4%	0.12
Vomiting
Yes	11	20.8%	5	20.0%	6	21.4%	0.90
No	42	79.2%	20	80.0%	22	78.6%	0.90
Abdominal pain
Yes	3	6.5%	2	10.0%	1	3.8%	0.40
No	43	93.5%	18	90.0%	25	96.2%	0.40
Distress
Yes	23	43.4%	23	92.0%	0	0.0%	< 0.01
No	30	56.6%	2	8.0%	28	100.0%	< 0.01
Outcome
Dead	1	1.9%	1	4.0%	0	0.0%	0.28
Alive	52	98.1%	24	96.0%	28	100.0%	0.28
Leukocyte count, × 10⁹/L	53	9232.08 (4755.19)	25	10,064.00 (4477.06)	28	8489.29 (4951.64)	0.10
Leukopenia (< 3.5 × 10⁹/L)
Yes	3	5.7%	0	0.0%	3	10.7%	0.09
No	50	94.3%	25	100.0%	25	89.3%	0.09
Leukocytosis(> 11 × 10^9/L)
Yes	17	32.1%	11	44.0%	6	21.4%	0.08
No	36	67.9%	14	56.0%	22	78.6%	0.08
Lymphocyte, %	53	26.249 (13.17)	25	29.22 (15.61)	28	23.59 (10.11)	0.25
Lymphopenia (< 20%)
Yes	21	39.6%	8	32.0%	13	46.4%	0.28
No	32	60.4%	17	68.0%	15	53.6%	0.28
Lymphocytosis(> 40%)
Yes	7	13.2%	6	24.0%	1	3.6%	0.03
No	46	86.8%	19	76.0%	27	96.4%	0.03
CRP, mg/L	53	22.5 (5.0–82.75)	25	23.0 (3.5–81.0)	28	15.5 (4.25–60.25)	0.82
ESR, mm/h	16	20.0 (14.0–59.25)	5	19.0 (13.0–85.0)	11	21.0 (14.0–51.0)	0.86
O₂ saturation, %	51	96.5 (94.0–97.75)	25	93.0 (86.5–95.0)	26	97.5 (95.0–98.0)	< 0.01
Respiratory rate	52	32.48 (13.36)	25	37.88 (15.66)	27	27.48 (8.35)	0.01
Antiviral therapy
Yes	11	20.8%	4	16.0%	7	25.0%	0.42
No	42	79.2%	21	84.0%	21	75.0%	0.42
Antibacterial therapy
Yes	49	92.5%	23	92.0%	26	92.9%	0.91
No	4	7.5%	2	8.0%	2	7.1%	0.91
Comorbid disease
Comorbid disease
Yes	20	37.7%	12	48.0%	8	28.6%	0.14
No	33	62.3%	13	52.0%	20	71.4%	0.14
G6PD deficiency
Yes	4	7.5%	3	12.0%	1	3.6%	0.25
No	49	92.5%	22	88.0%	27	96.4%	0.25
Cardiovascular
Yes	3	5.7%	2	8.0%	1	3.6%	0.49
No	50	94.3%	23	92.0%	27	96.4%	0.49
Gastrointestinal
Yes	3	5.7%	2	8.0%	1	3.6%	0.49
No	50	94.3%	23	92.0%	27	96.4%	0.49
Other comorbid diseases
Yes	6	11.3%	2	8.0%	4	14.3%	0.47
No	47	88.7%	23	92.0%	24	85.7%	0.47

CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Continuous and categorical variables were analyzed using independent t-test/Mann-Whitney U test and χ2/Fisher’s exact tests, respectively. P-value less than 0.05 was considered as significant

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Infectious Diseases

Contact us